Share

EORTC/SIOPE partnership to maximize quality of paediatric radiotherapy

The EORTC recently entered a partnership program with the European Society for Paediatric Oncology (SIOPe). The QUARTET project aims to establish a cross-European quality assurance platform for clinical trials using radiation therapy in the treatment of children and adolescents.

“Our goals are to increase cure rate in children and adolescents with cancer as well as the quality of life of childhood cancer survivors,” said Gilles Vassal, SIOPe President. “The partnership with EORTC will improve the quality of radiation therapy and contribute to these aims.”

“Quality assurance is essential in radiotherapy to ensure patients get the most benefit from their treatment with the minimum amount of risk,” said Samira Essiaf, Chief Executive Officer at SIOPe. “This project will help establish clear references for the reliable and efficient use of radiation therapy in paediatric oncology, and the EORTC’s rigorous quality control expertise in radiotherapy is key in our decision to enter in this partnership.”

“We are honored to be partnering with SIOPe to contribute to this important cross-European project,” said Yan Liu, clinical leader, medical department at EORTC. “Their dedication to improving quality of care and treatment for paediatric oncology patients is fundamentally aligned with the EORTC’s mission to improve treatment for all cancer patients.”

More information on the SIOPe website.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023